A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients
Brief description of study
This phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 in healthy participants and initial efficacy in CHB patients. A Safety Review Committee (SRC) will perform ongoing reviews of safety and tolerability based on available study data collected throughout the study. The study will be conducted in four Parts: Part A: SAD in healthy participants (double blinded) Part B: MD in healthy participants (double blinded) Part C: MD in CHB patients (open label) Part D: MD in CHB patients (double blinded; multiple sites)
Clinical Study Identifier: s23-00843
ClinicalTrials.gov Identifier: NCT05717686
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.